Citations 3
NCCN Guidelines® Insights: Colorectal Cancer Screening, Version 1.2024
Llor, Xavier , Abbass, Mohammad Ali , Chen, Christopher T. , Cooper, Gregory S. , Early, Dayna S., Friedman, Mark , Fudman, David , Giardiello, Francis M., Glaser, Kathryn , Gurudu, S, Hall, Michael J. , Issaka, Rachel B. , Kidambi, Trilokesh D. , Lazenby, Audrey J., Maratt, Jennifer K. , Markowitz, Arnold J. , Marsano, Joseph, Olortegui, Kinga Skowron , Peter, Shajan , Porter, Laura , Shafi, Mehnaz, Terdiman, Jonathan P., Vu, Peter , Wood, Elizabeth H., Cassara, Carly J., Gurudu, Surya, Ness, Reid M. , Bishu, Shrinivas , Huang, Lyen C. , Katona, Bryson W , May, Folasade P. , Mayer, Robert J. , Olortegui, Kinga S. , Patel, Swati , Stanich, Peter P. , Weiss, Jennifer M. , Wood, Elizabeth, Sambandam, Vaishnavi
Journal of the National Comprehensive Cancer Network | September 5, 2024 | Volume: 22 | Issue: 7 | Pages: 438-446
The NCCN Guidelines for Colorectal Cancer (CRC) Screening describe various colorectal screening modalities as well as recommended screening schedules for patients at average or increased risk of developing sporadic CRC. They are intended to aid physicians with clinical decision-making regarding CRC screening for patients without defined genetic syndromes. These NCCN Guidelines Insights focus on select recent updates to the NCCN Guidelines, including a section on primary and secondary CRC prevention, and provide context for the panel’s recommendations regarding the age at which to initiate screening in average-risk individuals and those with increased risk based on personal history of childhood, adolescent, and young adult cancer.
The significance of histological activity measurements in immune checkpoint inhibitor colitis
Pai, Rish K. , Pai, Reetesh K., Pai, Reetesh K., Brown, Ian , Choi, Won‐Tak , Kumarasinghe, M. Priyanthi , Gunawardena, Dilini , Kim, Baek Hui, Friedman, Mark , Ghayouri, Masoumeh, Lauwers, Gregory Y. , Brown, Ian S , Pai, Reetesh K., Pai, Reetesh K., Schaeffer, David F. , Farnell, David
Alimentary Pharmacology & Therapeutics | September 3, 2023 | Volume: 53 | Issue: 1 | Pages: 150-159
SummaryBackgroundColitis is a significant complication of immune checkpoint inhibitors (ICI). Currently, clinical and endoscopic severity are used to guide therapy.AimsTo investigate associations between clinical, endoscopic, and histological features with outcomesMethodsWe identified 149 patients from seven institutions with biopsy‐proven ICI colitis. Biopsies were evaluated for histological features including the Geboes score, and the Robarts histopathological index (RHI) was calculated. Clinical, endoscopic, and histological data were tested for associations with biological use and adverse colitis outcomes (biological‐refractory colitis, colectomy or death from colitis).ResultsThree mutually exclusive histological patterns were identified: acute colitis, chronic active colitis and microscopic colitis. Microscopic colitis was associated with older age (68.5 vs 61 years for acute colitis pattern, P = 0.02) and longer time to colitis (5.5 vs 3 months for the other patterns, P = 0.05). Biological use was associated with earlier time to colitis (2 vs 3 months, P = 0.04) and higher RHI (18 vs 12, P = 0.007). On multivariate analysis, RHI ≥14 was associated with biological use with an odds ratio of 4.5 (95% CI 1.4‐13.8; P = 0.01). Adverse colitis outcomes were associated with shorter time to colitis (2 vs 3 months, P = 0.008) and higher RHI (24 vs 14, P = 0.001). On multivariate analysis, RHI ≥24 was associated with adverse colitis outcomes with an odds ratio 9.5 (95% CI 2.1‐42.3 P = 0.003).ConclusionHistological activity as measured by RHI is the only factor independently associated with biological use and adverse colitis outcomes. Prospective studies are needed to validate these findings to determine if histological activity should be incorporated into therapeutic algorithms.
NCCN Guidelines Insights: Colorectal Cancer Screening, Version 2.2020
Provenzale, Dawn, Llor, Xavier , Abbadessa, Benjamin, Cooper, Gregory S. , Early, Dayna S., Friedman, Mark , Giardiello, Francis M., Glaser, Kathryn , Gurudu, Suryakanth, Halverson, Amy L. , Issaka, Rachel B. , Jain, Rishi , Kidambi, Trilokesh D. , Lazenby, Audrey J., Markowitz, Arnold J. , May, Folasade P. , Mehta, Shivan J. , Peter, Shajan , Stanich, Peter P. , Terdiman, Jonathan P., Keller, Jennifer , Dwyer, Mary A., Ogba, Ndiya , Ness, Reid M. , Weiss, Jennifer M. , Kanth, Priyanka , Maguire, Lillias Holmes , Mayer, Robert J. , Patel, Swati
Journal of the National Comprehensive Cancer Network | October 6, 2020 | Volume: 18 | Issue: 10 | Pages: 1312-1320
The NCCN Guidelines for Colorectal Cancer (CRC) Screening describe various colorectal screening modalities as well as recommended screening schedules for patients at average or increased risk of developing sporadic CRC. They are intended to aid physicians with clinical decision-making regarding CRC screening for patients without defined genetic syndromes. These NCCN Guidelines Insights focus on select recent updates to the NCCN Guidelines, including a section on primary and secondary CRC prevention, and provide context for the panel’s recommendations regarding the age to initiate screening in average risk individuals and follow-up for low-risk adenomas.